BioNTech SE (BNTX)

[Man6677]

BioNTech partners with Matinas BioPharma on delivery of mRNA vaccines
Apr. 11, 2022 9:45 AM ETBioNTech SE (BNTX)By: Jonathan Block, SA News Editor
mRNA Vaccines
kemalbas/iStock via Getty Images

BioNTech (NASDAQ:BNTX) will collaborate with Matinas BioPharma on the development of new delivery technology for mRNA vaccines, including potential oral vaccines.
Matinas has a proprietary lipid nanocrystal platform technology for intracellular delivery of nucleic acids and small molecules.
Terms call for Matinas will receive an upfront access fee to work exclusively with BioNTech (BNTX), as well as research funding from the German biotech. The companies are also discussing a license agreement for Matinas' platform technology.
Read why Seeking Alpha contributor SM Investor considers BioNTech a buy.


BNTX $$$$